274 related articles for article (PubMed ID: 24522940)
1. Isolated limb infusion as a model to test new agents to treat metastatic melanoma.
Lidsky ME; Speicher PJ; Jiang B; Tsutsui M; Tyler DS
J Surg Oncol; 2014 Mar; 109(4):357-65. PubMed ID: 24522940
[TBL] [Abstract][Full Text] [Related]
2. Regional therapy in metastatic melanoma: an update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion.
Rashid OM; Sloot S; Zager JS
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1355-64. PubMed ID: 25176398
[TBL] [Abstract][Full Text] [Related]
3. Isolated limb infusion: technical aspects.
Kroon HM; Huismans A; Waugh RC; Kam PC; Thompson JF
J Surg Oncol; 2014 Mar; 109(4):352-6. PubMed ID: 24374797
[TBL] [Abstract][Full Text] [Related]
4. In-transit melanoma: the role of alkylating-agent resistance in regional therapy.
Grubbs EG; Abdel-Wahab O; Cheng TY; Abdel-Wahab Z; Peterson B; Pruitt SK; Colvin OM; Friedman HS; Tyler DS
J Am Coll Surg; 2004 Sep; 199(3):419-27. PubMed ID: 15325612
[TBL] [Abstract][Full Text] [Related]
5. Perfusion and infusion for melanoma in-transit metastases in the era of effective systemic therapy.
Grünhagen DJ; Kroon HM; Verhoef C
Am Soc Clin Oncol Educ Book; 2015; ():e528-34. PubMed ID: 25993219
[TBL] [Abstract][Full Text] [Related]
6. Current status of hyperthermic limb perfusion for in-transit melanoma.
Ross MI
Int J Hyperthermia; 2008 May; 24(3):205-17. PubMed ID: 18392999
[TBL] [Abstract][Full Text] [Related]
7. Future directions in regional treatment strategies for melanoma and sarcoma.
Beasley GM; Ross MI; Tyler DS
Int J Hyperthermia; 2008 May; 24(3):301-9. PubMed ID: 18393007
[TBL] [Abstract][Full Text] [Related]
8. Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion?
Hoekstra HJ; Veerman K; van Ginkel RJ
J Surg Oncol; 2014 Mar; 109(4):338-47. PubMed ID: 24403098
[TBL] [Abstract][Full Text] [Related]
9. The role of regional chemotherapy in the management of extremity soft tissue malignancies.
Smith HG; Hayes AJ
Eur J Surg Oncol; 2016 Jan; 42(1):7-17. PubMed ID: 26382102
[TBL] [Abstract][Full Text] [Related]
10. Commentary on pharmacotherapy of regional melanoma therapy.
Zager JS; Delman KA
Expert Opin Pharmacother; 2010 Jan; 11(1):1-3. PubMed ID: 20001424
[TBL] [Abstract][Full Text] [Related]
11. International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients.
Teras J; Kroon HM; Miura JT; Kenyon-Smith T; Beasley GM; Mullen D; Farrow NE; Mosca PJ; Lowe MC; Farley CR; Potdar A; Daou H; Sun J; Carr M; Farma JM; Henderson MA; Speakman D; Serpell J; Delman KA; Smithers BM; Barbour A; Tyler DS; Coventry BJ; Zager JS; Thompson JF
Ann Surg Oncol; 2020 May; 27(5):1420-1429. PubMed ID: 32152775
[TBL] [Abstract][Full Text] [Related]
12. Isolated limb infusion: Institutional protocol and implementation.
Carr MJ; Sun J; Zager JS
J Surg Oncol; 2020 Jul; 122(1):99-105. PubMed ID: 32162353
[TBL] [Abstract][Full Text] [Related]
13. Use Patterns and Costs of Isolated Limb Perfusion and Infusion in the Treatment of Regional Metastatic Melanoma: A Retrospective Database Analysis.
Ma Q; Zhao Z; Barber BL; Shilkrut M
Adv Ther; 2016 Feb; 33(2):282-9. PubMed ID: 26797898
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis.
Santillan AA; Delman KA; Beasley GM; Mosca PJ; Hochwald SN; Grobmyer SR; Andtbacka RH; Noyes RD; Kane JM; Ross MI; Tyler DS; Zager JS
Ann Surg Oncol; 2009 Sep; 16(9):2570-8. PubMed ID: 19543771
[TBL] [Abstract][Full Text] [Related]
15. Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha.
Deroose JP; Eggermont AM; van Geel AN; Verhoef C
Curr Opin Oncol; 2011 Mar; 23(2):183-8. PubMed ID: 21150602
[TBL] [Abstract][Full Text] [Related]
16. Isolated limb infusion with melphalan and actinomycin D for melanoma: a systematic review.
Kroon HM; Huismans AM; Kam PC; Thompson JF
J Surg Oncol; 2014 Mar; 109(4):348-51. PubMed ID: 24522939
[TBL] [Abstract][Full Text] [Related]
17. Predicting disease progression after regional therapy for in-transit melanoma.
Lidsky ME; Turley RS; Beasley GM; Sharma K; Tyler DS
JAMA Surg; 2013 Jun; 148(6):493-8. PubMed ID: 23558401
[TBL] [Abstract][Full Text] [Related]
18. Isolated Limb Perfusion for Stage III Melanoma: Does It Still Have a Role in the Present Era of Effective Systemic Therapy?
Grünhagen DJ; Verhoef C
Oncology (Williston Park); 2016 Dec; 30(12):1045-52. PubMed ID: 27987194
[TBL] [Abstract][Full Text] [Related]
19. Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response.
Aloia TA; Grubbs E; Onaitis M; Mosca PJ; Cheng TY; Seigler H; Tyler DS
Arch Surg; 2005 Nov; 140(11):1115-20. PubMed ID: 16301451
[TBL] [Abstract][Full Text] [Related]
20. First Eastern European experience of isolated limb infusion for in-transit metastatic melanoma confined to the limb: Is it still an effective treatment option in the modern era?
Teras J; Kroon HM; Thompson JF; Teras M; Pata P; Mägi A; Teras RM; Boudinot SR
Eur J Surg Oncol; 2020 Feb; 46(2):272-276. PubMed ID: 31748147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
